It appears reasonable to assume that insulin-sensitizers drugs, by reducing the carcinogenic effects of obesity and insulin resistance, might be employed for long-term chemoprevention in women at high risk of endometrial cancer. The gene discussed is INS; the disease is endometrial cancer.